Method for diagnosis of physiological states by detecting patterns of volatile analytes

• US 20080220984A1
• Filed: 02/11/2008
• Published: 09/11/2008
• Est. Priority Date: 03/10/2004
• Status: Abandoned Application

• Current Assignee: The Research Foundation for The State University of New York (State University of New York)
• Original Assignee: The Research Foundation for The State University of New York (State University of New York)
• Inventors: Titus, Albert H., Cartwright, Alexander N., Bright, Frank V., Hicks, Wesley, Govindaraju, Venugopal
• Application Number:
  US12/069,662
• Publication Number:
  US 20080220984A1
• Time in Patent Office: Days
• US Class Current: 506/12
• CPC Class Codes: G01N 33/52 Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements immunological elements G01N33/54386; involving labelled immunochemicals G01N33/58; for haemoglobin or occult blood G01N33/72

Abstract

Provided is a non-invasive method for identification of non-physiological, physiological or diseased states based on the volatiles in gas or biogas samples from individuals. The method uses a sensor array comprising a plurality of distinct sensors which differ from other sensors by the sensing molecules or the sol-gel holding material composition. In response to a combination of volatiles, a pattern of responses is generated which can be correlated to particular non-physiological, physiological or diseased state.

Claims

1. ) A method for diagnosis of a physiological or diseased state comprising the steps of:

a) providing a sensor array comprising a plurality of distinct sensors, wherein each sensors comprises a holding material and a sensing molecule, wherein the holding material is a sol-gel derived material, wherein each distinct sensor differs from other distinct sensors in the holding material, the sensing molecule or both;

b) exposing the sensor array to a test biogas sample;

c) recording the response of a plurality of distinct sensors in the sensor array;

d) generating a pattern based on the response of the plurality of distinct sensors; and

e) comparing the pattern obtained from the test biogas sample to a pattern obtained from a control biogas sample to determine the presence or absence of a physiological or diseased state.

2. ) The method of claim 1, wherein step e) is carried out by visual inspection.

3. ) The method of claim 1, wherein the diseased state is selected from the group consisting of diabetes and cancer.

4. ) The method of claim 1, wherein the sensing molecules are selected from the group consisting of Rhodamine 6G, Rhodamine B, NBD [nitrobenzo-2-oxa-1,3-diazole], tris(4,7′

-diphenyl-1,10′

-phenathroline) ruthenium(II), tris(1,10′

-phenathroline)ruthenium(II), platinum octaethylporphyrin, pyrene, PRODAN [6-propionyl-2-(N,N-dimethylamino)naphthalene], and DCM [4-(dicyanomethylene)-2-methyl-6-[p-(dimethyl-amino)styryl]-4H-pyran], and Coumarin 153.

5. ) The method of claim 1, wherein the sol-gel derived material is xerogel or aerogel.

6. ) The method of claim 5, wherein the xerogel is fabricated from precursors selected from the group consisting of Si(OEt)₄, R—

Si(OEt)₄, (EtO)₃—

Si—

R′

—

Si(OEt)₃ where R=alkyl, (CH₂)₃—

CHO, (CH₂)₃—

NH₂, phenyl, phenyl-NH₂, (CH₂)₂-pyridyl, cycloaminopropyl, CH₂—

NH-phenyl, (CH₂)₃—

N(C₂H₄—

OH)₂(CH₂)₃—

N⁺—

(R″

)₃, dihydroimidazole, ureidopropyl, and ethylene diamine tetraacetic acid (EDTA);

R′

=(CH₂)₃—

NH—

(CH₂)₃, (CH₂)₃—

NH—

C₂H₄—

NH(CH₂)₃, phenyl, and biphenyl and combinations thereof.

7. ) The method of claim 6) wherein the precursors are selected from the group consisting of Si(OEt)₄;

(EtO)₃Si-phenyl-NH₂; and

(EtO)₃—

Si—

(CH₂)₃—

NH—

(CH₂)₃—

Si(OEt)₃, and the sensing molecules are selected from the group consisting of tris(4,7′

-diphenyl-1,10′

-phenathroline)ruthenium(II), Rhodamine B and [4-(dicyanomethylene)-2-methyl-6-[p-(dimethyl-amino)styryl]-4H-pyran].

8. ) The method of claim 1, wherein the number of distinct sensor elements in the sensor array is selected from the group consisting of 10 to 100, 101 to 1,000, 1,001 to 10,000 and 10,000 to 100,000.

9. ) A method for diagnosis of a physiological or diseased state comprising the steps of:

a) providing a sensor array comprising a plurality of distinct sensors, wherein each sensors comprises a holding material and a sensing molecule, wherein the holding material is a sol-gel derived material, wherein each distinct sensor differs from other distinct sensors in the holding material, the sensing molecule or both;

b) exposing the sensor array to a test biogas sample;

c) recording the response of a plurality of distinct sensors in the sensor array; and

d) subjecting the response of the plurality of distinct sensors to a predetermined rule set, wherein the predetermined rule set defines a particular physiological or diseased state, thereby identifying the presence or absence of a particular physiological or diseased state.

10. ) The method of claim 9, wherein the known set of responses is obtained by training a neural network using responses of sensors exposed to biogas sample from individuals with known physiological states.

11. ) The method of claim 9, wherein the sensing molecules are selected from the group consisting of Rhodamine 6G, Rhodamine B, NBD [nitrobenzo-2-oxa-1,3-diazole], tris(4,7′

-diphenyl-1,10′

-phenathroline) ruthenium(II), tris(1,10′

-phenathroline)ruthenium(II), platinum octaethylporphyrin, pyrene, PRODAN [6-propionyl-2-(N,N-dimethylamino)naphthalene], and DCM [4-(dicyanomethylene)-2-methyl-6-[p-(dimethyl-amino)styryl]-4H-pyran] and Coumarin 153.

12. ) The method of claim 9, wherein the sol-gel derived material is a xerogel or an aerogel.

13. ) The method of claim 12, wherein the xerogel is fabricated using precursors selected from the group consisting of Si(OEt)₄, R—

Si(OEt)₄, (EtO)₃—

Si—

R′

—

Si(OEt)₃ where R=alkyl, (CH₂)₃—

CHO, (CH₂)₃—

NH₂, phenyl, phenyl-NH₂, (CH₂)₂-pyridyl, cycloaminopropyl, CH₂—

NH-phenyl, (CH₂)₃—

N(C₂H₄—

OH)₂(CH₂)₃—

N⁺—

(R″

)₃, dihydroimidazole, ureidopropyl, and ethylene diamine tetraacetic acid (EDTA);

R′

=(CH₂)₃—

NH—

(CH₂)₃, (CH₂)₃—

NH—

C₂H₄—

NH(CH₂)₃, phenyl, and biphenyl, and combinations thereof.

14. ) The method of claim 9, wherein the number of distinct sensor elements in the sensor array is selected from the group consisting of 10 to 100, 101 to 1,000, 1,001 to 10,000, and 10,000 to 100,000.

15. ) The method of claim 9, wherein the diseased state is selected from the group consisting of diabetes and cancer.

16. ) A method for matching a test gaseous sample to a predetermined control gas sample comprising the steps of:

a) providing a sensor array comprising a plurality of distinct sensors, wherein each sensors comprises a holding material and a sensing molecule, wherein the holding material is a sol-gel derived material, wherein each distinct sensor differs from other distinct sensors in the holding material, the sensing molecule or both;

b) exposing the sensor array to a test gas sample;

c) recording the response of a plurality of distinct sensors in the sensor array; and

d) comparing the response from a plurality of distinct sensors from the test gas sample to the response from the predetermined control gas sample to determine whether or not the test gas sample matches the predetermined control sample.

17. ) The method of claim 16, wherein the comparing in step d) is carried out by visual inspection.

18. ) The method of claim 16, wherein the comparing in step d) is carried out by subjecting the response of the plurality of distinct sensors to a predetermined rule set, wherein the predetermined rule set defines the predetermined control gas, thereby enabling matching of the test gas sample with the predetermined control gas sample.

19. ) The method of claim 16, wherein the sol-gel derived material is a xerogel or an aerogel.

20. ) The method of claim 19, wherein the sensing molecules are selected from the group consisting of Rhodamine 6G, Rhodamine B, NBD [nitrobenzo-2-oxa-1,3-diazole], tris(4,7′

-diphenyl-1,10′

-phenathroline)ruthenium(II), tris(1,10′

-phenathroline)ruthenium(II), platinum octaethylporphyrin, pyrene, PRODAN [6-propionyl-2-(N,N-dimethylamino)naphthalene], and DCM [4-(dicyanomethylene)-2-methyl-6-[p-(dimethyl-amino)styryl]-4H-pyran], and Coumarin 153, and the xerogel is fabricated using precursors selected from the group consisting of Si(OEt)₄, R—

Si(OEt)₄, (EtO)₃—

Si—

R′

—

Si(OEt)₃ where R=alkyl, (CH₂)₃—

CHO, (CH₂)₃—

NH₂, phenyl, phenyl-NH₂, (CH₂)₂-pyridyl, cycloaminopropyl, CH₂—

NH-phenyl, (CH₂)₃—

N(C₂H₄—

OH)₂ (CH₂)₃—

N⁺—

(R″

)₃, dihydroimidazole, ureidopropyl, and ethylene diamine tetraacetic acid (EDTA);

R′

=(CH₂)₃—

NH—

(CH₂)₃, (CH₂)₃—

NH—

C₂H₄—

NH(CH₂)₃, phenyl, biphenyl and combinations thereof.